Neurobo Pharmaceuticals Inc
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has com… Read more
Neurobo Pharmaceuticals Inc (NRBO) - Net Assets
Latest net assets as of September 2024: $12.95 Million USD
Based on the latest financial reports, Neurobo Pharmaceuticals Inc (NRBO) has net assets worth $12.95 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.15 Million) and total liabilities ($9.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.95 Million |
| % of Total Assets | 58.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | 35.74% |
| 10-Year Change | N/A |
| Growth Volatility | 761.98 |
Neurobo Pharmaceuticals Inc - Net Assets Trend (2014–2023)
This chart illustrates how Neurobo Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neurobo Pharmaceuticals Inc (2014–2023)
The table below shows the annual net assets of Neurobo Pharmaceuticals Inc from 2014 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $16.68 Million | -23.29% |
| 2022-12-31 | $21.75 Million | +49.00% |
| 2021-12-31 | $14.60 Million | +102.65% |
| 2020-12-31 | $7.20 Million | -41.40% |
| 2019-12-31 | $12.29 Million | +116.10% |
| 2018-12-31 | $-76.34 Million | -2037.00% |
| 2017-12-31 | $3.94 Million | -80.90% |
| 2016-12-31 | $20.63 Million | +266.66% |
| 2015-12-31 | $-12.38 Million | -2231.45% |
| 2014-12-31 | $-531.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurobo Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10768100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.03% |
| Other Components | $124.94 Million | 748.85% |
| Total Equity | $16.68 Million | 100.00% |
Neurobo Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Neurobo Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marvel Biosciences Corp.
PINK:MBCOF
|
$4.03 Million |
|
Acrux Limited
PINK:ARUXF
|
$4.04 Million |
|
VIOL Co. Ltd
KQ:335890
|
$4.04 Million |
|
Stenocare AS
CO:STENO
|
$4.04 Million |
|
Synertec Corporation Ltd
AU:SOP
|
$4.03 Million |
|
Digicontent Limited
NSE:DGCONTENT
|
$4.03 Million |
|
NSX Ltd
AU:NSX
|
$4.03 Million |
|
XOX Technology Bhd
KLSE:0017
|
$4.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurobo Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 21,750,000 to 16,685,000, a change of -5,065,000 (-23.3%).
- Net loss of 12,470,000 reduced equity.
- Other factors increased equity by 7,405,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.47 Million | -74.74% |
| Other Changes | $7.41 Million | +44.38% |
| Total Change | $- | -23.29% |
Book Value vs Market Value Analysis
This analysis compares Neurobo Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-75.13 | $1.92 | x |
| 2015-12-31 | $-1751.56 | $1.92 | x |
| 2016-12-31 | $2663.91 | $1.92 | x |
| 2017-12-31 | $285.62 | $1.92 | x |
| 2018-12-31 | $-538.68 | $1.92 | x |
| 2019-12-31 | $564.71 | $1.92 | x |
| 2020-12-31 | $106.60 | $1.92 | x |
| 2021-12-31 | $151.37 | $1.92 | x |
| 2022-12-31 | $67.61 | $1.92 | x |
| 2023-12-31 | $3.29 | $1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurobo Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -178142.86%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-74.74%) is above the historical average (-171.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-266.90K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.79 Million |
| 2016 | -70.70% | 0.00% | 0.00x | 1.20x | $-16.65 Million |
| 2017 | -847.88% | 0.00% | 0.00x | 4.83x | $-33.81 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.00 Million |
| 2019 | -182.48% | 0.00% | 0.00x | 1.18x | $-23.66 Million |
| 2020 | -410.84% | 0.00% | 0.00x | 1.52x | $-30.31 Million |
| 2021 | -104.28% | 0.00% | 0.00x | 1.15x | $-16.68 Million |
| 2022 | -28.11% | 0.00% | 0.00x | 1.54x | $-8.29 Million |
| 2023 | -74.74% | -178142.86% | 0.00x | 1.37x | $-14.14 Million |
Industry Comparison
This section compares Neurobo Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurobo Pharmaceuticals Inc (NRBO) | $12.95 Million | 0.00% | 0.71x | $4.03 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |